Authors

Latest:

Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases

Doctors discuss the effectiveness of different treatment combinations for patients with BRAF-mutated metastatic melanoma and brain metastases, highlighting that consideration of patient preferences is essential in making treatment decisions.

Michael Postow, MD, Memorial Sloan Kettering Cancer Center

Michael Pulsipher, MD

Latest:

Pivotal Data in NHL and Pediatric Cancers at ASH 2021: Insight From Drs. Loretta Nastoupil and Michael Pulsipher

OncLive speaks with Dr. Loretta Nastoupil on some exciting non-Hodgkin lymphoma studies and Dr. Michael Pulsipher on some intriguing pediatric cancer research.

Michael Pulsipher, MD, Children

Michael R. Bishop, MD, University of Chicago

Latest:

Dr Bishop on the Rationale for Evaluating Anito-Cel in R/R Myeloma

Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.

Michael R. Charlton, MD, MBBS

Latest:

Dr. Charlton on the Interaction Between Liver Disease and HCC

Michael R. Charlton, MD, MBBS, discusses the interaction between liver disease and hepatocellular carcinoma.

Michael R. Harrison, MD

Latest:

Dr. Harrison on the Investigation of Combination Strategies in Frontline RCC

Michael R. Harrison, MD, discusses several ongoing or upcoming studies that may change the treatment paradigm in renal cell carcinoma.

Michael R. Harrison, MD, Duke Cancer Institute

Michael R. Page, PharmD, RPh

Latest:

Chemotherapy Parity Laws Ignore Cost, Quality Question

With the FDA approval of several oral chemotherapy agents, the cost of medications to treat cancer is increasing rapidly. To control costs, legislators, patient advocates, and physicians have pushed for oral chemotherapy parity laws.

Michael Reff, RPh, MBA National Community Oncology Dispensing Association

Michael Rosenzweig, MD

Latest:

Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.

Michael Rotkowitz, MD

Latest:

Dr. Rotkowitz Describes Challenges Facing Immunotherapy

Michael Rotkowitz, MD, says that one of the main challenges and a leading goal of immunotherapy research is measuring response to justify the administration.

Michael S. Cookson, MD, MMHC, University of Oklahoma Health Sciences Center

Michael S. Ewer, MD, MPH, JD, LLM, MBA

Latest:

Dr. Ewer Discusses Supportive Care

Dr. Michael S. Ewer, from The University of Texas MD Anderson Cancer Center, on Supportive Care

Michael S. Lee, MD

Latest:

Dr. Lee on Trial Data Evaluating the Atezolizumab/Bevacizumab in Unresectable HCC

Michael S. Lee, MD, discusses trial data evaluating the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in unresectable hepatocellular carcinoma.

Michael Sawyer, MD

Latest:

Dr. Sawyer on LBM Outcomes With Siltuximab in Multicentric Castleman's Disease

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman's disease who received siltuximab (Sylvant).

Michael Schuster, MD

Michael Shuster, MD

Michael Simon, MD

Latest:

Dr. Simon on Genomic Assays for Patients With Breast Cancer

Michael Simon, MD, MPH, medical oncologist, Karmanos Cancer Institute, discusses genomic assays for patients with breast cancer.

Michael Snyder, Lee Goldberg

Latest:

Payer Management of Oncology Gets Serious

Health plans continue to seek methods to curtail cancer costs.